Loading...

VOR VOR BIOPHARMA INC Company Mergers 8-K Filing

VR B

VR

VOR BIOPHARMA INC

(VOR)

2025 8-K

Summary

Summary

Stock Split Update

Corporate Presentation Update

Management Changes

Stockholder Approval

Licensing Agreement

Equity Offerings

Workforce Reduction

Noncompliance with Listing ...

Management Change

Stock Option Repricing

Board Appointment

Private Placement

Clinical Data Update

CFO Appointment

Resignation and Appointment

Equity Incentive Plan Amend...

Appointment of Director

Clinical Update

Annual Meeting of Stockholders

Resignation of Director

Clinical Update

External Links:

On June 25, 2025, Vor Biopharma Inc. entered a license agreement with RemeGen Co., Ltd. for exclusive rights to develop and commercialize the fusion protein telitacicept outside Greater China, for an upfront payment of $125 million, and announced a private placement resulting in $175 million for new equity. Additionally, Dr. Robert Ang resigned as CEO and Jean-Paul Kress was appointed to replace him as CEO and Chairman.

AI Assistant

VOR BIOPHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.